JP7007278B2 - サイログロブリンの測定方法及び測定試薬 - Google Patents
サイログロブリンの測定方法及び測定試薬 Download PDFInfo
- Publication number
- JP7007278B2 JP7007278B2 JP2018538407A JP2018538407A JP7007278B2 JP 7007278 B2 JP7007278 B2 JP 7007278B2 JP 2018538407 A JP2018538407 A JP 2018538407A JP 2018538407 A JP2018538407 A JP 2018538407A JP 7007278 B2 JP7007278 B2 JP 7007278B2
- Authority
- JP
- Japan
- Prior art keywords
- sample
- antibody
- pretreatment
- solution
- thyroglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960002175 thyroglobulin Drugs 0.000 title claims description 22
- 108010034949 Thyroglobulin Proteins 0.000 title claims description 17
- 102000009843 Thyroglobulin Human genes 0.000 title claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 14
- 238000005259 measurement Methods 0.000 title description 10
- 238000000691 measurement method Methods 0.000 title description 2
- 238000000034 method Methods 0.000 claims description 74
- 239000007788 liquid Substances 0.000 claims description 28
- 238000003018 immunoassay Methods 0.000 claims description 27
- 239000002535 acidifier Substances 0.000 claims description 26
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 18
- 239000003945 anionic surfactant Substances 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 8
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 claims description 3
- YFVGRULMIQXYNE-UHFFFAOYSA-M lithium;dodecyl sulfate Chemical compound [Li+].CCCCCCCCCCCCOS([O-])(=O)=O YFVGRULMIQXYNE-UHFFFAOYSA-M 0.000 claims description 3
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 claims description 3
- 239000000523 sample Substances 0.000 description 95
- 239000000243 solution Substances 0.000 description 48
- 239000000427 antigen Substances 0.000 description 42
- 102000036639 antigens Human genes 0.000 description 42
- 108091007433 antigens Proteins 0.000 description 42
- 239000007790 solid phase Substances 0.000 description 32
- 230000020477 pH reduction Effects 0.000 description 26
- 238000012360 testing method Methods 0.000 description 23
- 238000002835 absorbance Methods 0.000 description 20
- 239000012472 biological sample Substances 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- 238000005406 washing Methods 0.000 description 16
- 239000012086 standard solution Substances 0.000 description 15
- 238000002411 thermogravimetry Methods 0.000 description 15
- 238000010517 secondary reaction Methods 0.000 description 13
- 239000004094 surface-active agent Substances 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000007853 buffer solution Substances 0.000 description 9
- 238000011088 calibration curve Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- 239000003093 cationic surfactant Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000002523 gelfiltration Methods 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 238000003127 radioimmunoassay Methods 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000003325 follicular Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000004879 turbidimetry Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 239000004816 latex Substances 0.000 description 4
- 229920000126 latex Polymers 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 102000013415 peroxidase activity proteins Human genes 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 210000001685 thyroid gland Anatomy 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 3
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 3
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 3
- 101000800133 Homo sapiens Thyroglobulin Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000024799 Thyroid disease Diseases 0.000 description 3
- 102000005936 beta-Galactosidase Human genes 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 3
- 102000034287 fluorescent proteins Human genes 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 238000003317 immunochromatography Methods 0.000 description 3
- 239000000696 magnetic material Substances 0.000 description 3
- 239000006249 magnetic particle Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000941 radioactive substance Substances 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- -1 4-methylumbelliferyl galactoside Chemical class 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- XYIPYISRNJUPBA-UHFFFAOYSA-N [3-(3'-methoxyspiro[adamantane-2,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC(C3)CC2C4)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 XYIPYISRNJUPBA-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012767 chemiluminescent enzyme immunoassay Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229940080237 sodium caseinate Drugs 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 208000021510 thyroid gland disease Diseases 0.000 description 2
- 239000005495 thyroid hormone Substances 0.000 description 2
- 229940036555 thyroid hormone Drugs 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- GKQHIYSTBXDYNQ-UHFFFAOYSA-M 1-dodecylpyridin-1-ium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+]1=CC=CC=C1 GKQHIYSTBXDYNQ-UHFFFAOYSA-M 0.000 description 1
- YFVBASFBIJFBAI-UHFFFAOYSA-M 1-tetradecylpyridin-1-ium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+]1=CC=CC=C1 YFVBASFBIJFBAI-UHFFFAOYSA-M 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QAXLTZBBDSDRPW-UHFFFAOYSA-N 2-(diethylamino)ethanethiol;hydron;chloride Chemical compound Cl.CCN(CC)CCS QAXLTZBBDSDRPW-UHFFFAOYSA-N 0.000 description 1
- UMTZYGZMIJRCFG-UHFFFAOYSA-N 3-phenyldioxetane Chemical compound C1OOC1C1=CC=CC=C1 UMTZYGZMIJRCFG-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010010510 Congenital hypothyroidism Diseases 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- HXWGXXDEYMNGCT-UHFFFAOYSA-M decyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCC[N+](C)(C)C HXWGXXDEYMNGCT-UHFFFAOYSA-M 0.000 description 1
- PLMFYJJFUUUCRZ-UHFFFAOYSA-M decyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)C PLMFYJJFUUUCRZ-UHFFFAOYSA-M 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 208000015799 differentiated thyroid carcinoma Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000002061 nanopillar Substances 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000010882 preoperative diagnosis Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- GLFDLEXFOHUASB-UHFFFAOYSA-N trimethyl(tetradecyl)azanium Chemical compound CCCCCCCCCCCCCC[N+](C)(C)C GLFDLEXFOHUASB-UHFFFAOYSA-N 0.000 description 1
- CEYYIKYYFSTQRU-UHFFFAOYSA-M trimethyl(tetradecyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+](C)(C)C CEYYIKYYFSTQRU-UHFFFAOYSA-M 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/046—Thyroid disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
(1)生体から分離された試料と、酸性化剤又は陰イオン性界面活性剤を含む前処理液とを混和する前処理工程を含む、生体から分離された試料中のサイログロブリンをイムノアッセイにより測定する方法。
(2)前記前処理液が酸性化剤を含み、前処理工程における酸性化剤の終濃度が0.05N超0.5N以下である、(1)に記載の方法。
(3)前記陰イオン性界面活性剤が、ドデシル硫酸ナトリウム、ドデシル硫酸リチウム又はドデシルベンゼンスルホン酸ナトリウムである、(1)記載の方法。
(4)前記前処理工程が、加熱条件下で行われる、(1)~(3)のいずれか1項に記載の方法。
(5)酸性化剤又は陰イオン性界面活性剤を含む前処理液を備える、サイログロブリンのイムノアッセイ用試薬。
本発明で測定されるサイログロブリン(Tg)は、任意の動物由来のTgであるが、好ましくは、哺乳動物(例、ヒト、サル、チンパンジー等の霊長類;マウス、ラット、ウサギ等の齧歯類;イヌ、ネコ等の愛玩動物;ブタ、ウシ等の家畜;ウマ、ヒツジ等の使役動物)由来のTgであり、より好ましくは霊長類由来のTgであり、特に好ましくは、ヒト由来のTgである。
本発明の方法は、生体試料と抗体とを反応させる免疫反応により生体試料中に存在するTgを測定する方法であるが、免疫反応(反応工程)の前に、生体試料と前処理液とを混和することによる前処理工程を含むことを特徴とする。前処理工程により、Tgを自己抗体(TgAb)等から遊離させた状態とすることができる。前処理液は、界面活性剤及び酸性化剤のいずれかを含んでいてもよく、両方を含んでいてもよい。好ましくは、前処理液は、界面活性剤又は酸性化剤のいずれかを含む。
本発明の方法の上記前処理工程で得られた生体試料混和液は、次いでイムノアッセイの反応工程に供される。反応工程においては、生体試料混和液を緩衝液と混合させ、混合液中の抗原をTgに対する抗体と反応させる。なお、Tgのイムノアッセイ自体は種々の方法が周知であり、Tgを定量可能ないずれのイムノアッセイをも採用することができる。
一次抗体又は二次抗体に標識を用いた場合、使用する標識に適した方法、例えば酵素標識を用いた場合は酵素の基質を添加することによって、検出する。例えば、アルカリホスファターゼ(ALP)を標識抗体として用いた場合は、3-(2’-スピロアダマンタン)-4-メトキシ-4-(3’-ホスホリルオキシ)フェニル-1,2-ジオキセタン・2ナトリウム塩(AMPPD)を酵素基質として用いた化学発光酵素イムノアッセイ法(CLEIA)の系とすることができる。
本発明のTgの測定試薬は、上述のTgの測定方法を実現し得る測定試薬である。本発明の測定試薬は、通常のイムノアッセイに使用される構成に加え、界面活性剤及び酸性化剤のいずれか又は両方を含む前処理液を構成成分として含むことを特徴とする。
(1)抗サイログロブリン抗体プレートの作製
ポリスチレン製96穴マイクロウェルプレート(Nunc社製)に抗Tgマウス抗体5F9(AbD Serotec社製)を5μg/mL含む抗体希釈液(0.1M 炭酸水素ナトリウム、0.1M 塩化ナトリウム、pH9.6)を100μL/ウェル分注し、4℃で一晩インキュベーションを行った。マイクロウェルプレートをPBSで3回洗浄し、次いで、ブロッキング液(1.0% BSA、3% スクロース、0.05% ProClin(登録商標)300を含むPBS)を200μL/ウェル分注し、室温で2時間インキュベーションを行った。ブロッキング液を除去した後、プレートを真空乾燥させ、抗Tg抗体プレートとした。
甲状腺関連疾患の患者血清検体45例について、各50μLを酸性化前処理液(2.5M 尿素、0.42M 塩酸、0.08M クエン酸水和物、2.5% マルトース、10.0% CTAB、4.9% TritonX-100(商品名))50μLと混和し、37℃で6分間加温した。次いで、緩衝液(500mM Tris-HCl、200mM NaCl、EDTA3Na、10.0% BSA、50μg/mL マウスIgG、pH9.2)を100μL加え、酸性化前処理サンプルとした。
各酸性化前処理サンプルと各未処理サンプルを、抗Tg抗体プレートに150μLずつ分注し、室温で1時間インキュベーションした(一次反応)。洗浄液(0.05% Tween20/PBS)で5回洗浄した後、ビオチン化抗Tg抗体5E6(AbD Serotec社製)を二次反応液(24mM リン酸二水素カリウム、76mM リン酸水素二カリウム、1.0% BSA、1.0% PVP、0.05% カゼインナトリウム、0.05% Tween20、0.05% 塩化ナトリウム、20mM EDTA2Na、0.1% ProClin300(登録商標)、pH7.0)で2μg/mLに希釈した二次抗体液を100μL/ウェル分注し、室温で1時間反応させた(二次反応)。洗浄液で5回洗浄した後、二次反応液で10000倍に希釈したHRP標識ストレプトアビジン(ロシュ社製)液を100μ/ウェル分注し、室温で30分間反応させた。洗浄液で5回洗浄した後、TMB基質液(ナカライテスク社製)を100μL/ウェル分注し、室温で15分間暗所に静置した。1N硫酸を100μL/ウェル分注して反応を停止させ、各ウェルの450nm/630nmの吸光度を測定した。各検体のTg測定値は、酸性化前処理標準液、未処理標準液をそれぞれ使用して作成した検量線に基づいて算出した。0ng/mLの標準液よりも低い吸光度を示す検体は全て0ng/mLとした。
各検体及び標準液の酸性化前処理サンプルと未処理サンプルの測定結果を表1に示す。また、酸性化前処理検体と未処理検体の測定値の全体の相関性を図1に、特に吸光度の低い領域の相関性を図2に示す。特にTgAb高値の未処理検体で0ng/mLを下回る吸光度を示す傾向があったが、前処理により吸光度が上昇した。これまでTgの測定ができなかった検体について、測定が可能になったことが示唆された。
実施例1で前処理により測定値が増加したNo.6の検体と、前処理によって測定値に変化がなかったNo.13の検体について、未処理サンプル、酸性化前処理サンプルを調製し、ゲル濾過クロマログラフィーを行った。
カラム:Superose6 10/30(商品名)
分離緩衝液:PBS, 0.08% CHAPS, 0.05% Tween20(商品名), 1mM EDTA2Na, pH7.4
流速:0.5mL/分
回収範囲:4mL~24mL(0.5mL/画分)
酸性化前処理に用いる酸性化剤の至適濃度を検討した。TgAb陽性で、Tg測定値へのTgAbの影響(干渉)が比較的弱かったNo.13、No.16の検体、TgAb陽性でTgAbの干渉が比較的強かったNo.19、No.44の検体、及びTgAb陰性のNo.25、No.30の検体の計6検体について、各50μLを、塩酸を2N、1N、0.8N、0.6N、0.4N、0.2N、0.1N、0.05N、0.025N、0N含む以外は実施例1の酸性化前処理液と同様に調製した酸性化前処理液50μLと混和し、37℃で6分間加温した。次いで、上記塩酸と等量の水酸化ナトリウム溶液を100μL加えて中和した。中和後の溶液に実施例1と同様の二次反応液200μLを添加し、酸性化前処理サンプルとした。各酸性化前処理サンプルについて、実施例1と同様のELISA法に供して、450nm/630nmの吸光度データを得た。
甲状腺関連疾患の患者血清検体51例について、各50μLをSDS前処理液(347mM SDS、2mM EDTA2Na、10mM Tris-HCl、pH7.2)100μLと混和し、1000rpmの振とう条件下で80℃で5分間加熱した。次いで、中和液(1.2% C16TAC、4% CHAPS、2.9% Tween20(商品名))で4倍希釈し、室温で30分間インキュベーションした後、15℃、12000rpmの条件下で15分間遠心分離し、得られた上清をSDS前処理サンプルとした。同時に、同じ検体について、前処理液に代えてPBS100μLを使用したことと、加熱を行わないこと以外は、上記SDS前処理と同様の処理を行い、得られたサンプルを未処理サンプルとした。既知濃度の精製ヒトTg(BBI solutions社製)をTgAb陰性血清で希釈し、0、6、30、60、300、600、2400、4800ng/mLの標準液を調製した。各標準液についても、上記と同様の方法でSDS前処理サンプルと未処理サンプルを調製した。
別途、各検体のTgAb値をルミパルス(登録商標)TgAb(富士レビオ社製)で測定した。
Claims (5)
- 生体から分離された試料と、酸性化剤又は陰イオン性界面活性剤を含む前処理液とを混和する前処理工程を含む、生体から分離された試料中のサイログロブリンをイムノアッセイにより測定する方法。
- 前記前処理液が酸性化剤を含み、前処理工程における酸性化剤の終濃度が0.05N超0.5N以下である、請求項1に記載の方法。
- 前記陰イオン性界面活性剤が、ドデシル硫酸ナトリウム、ドデシル硫酸リチウム又はドデシルベンゼンスルホン酸ナトリウムである、請求項1記載の方法。
- 前記前処理工程が、加熱条件下で行われる、請求項1~3のいずれか1項に記載の方法。
- 酸性化剤又は陰イオン性界面活性剤を含む前処理液を備える、サイログロブリンのイムノアッセイ用試薬。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016173835 | 2016-09-06 | ||
JP2016173835 | 2016-09-06 | ||
PCT/JP2017/031869 WO2018047792A1 (ja) | 2016-09-06 | 2017-09-05 | サイログロブリンの測定方法及び測定試薬 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2018047792A1 JPWO2018047792A1 (ja) | 2019-06-24 |
JP7007278B2 true JP7007278B2 (ja) | 2022-02-10 |
Family
ID=61562102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018538407A Active JP7007278B2 (ja) | 2016-09-06 | 2017-09-05 | サイログロブリンの測定方法及び測定試薬 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11768209B2 (ja) |
EP (2) | EP3929584A1 (ja) |
JP (1) | JP7007278B2 (ja) |
CN (2) | CN109477832A (ja) |
TW (1) | TW201812298A (ja) |
WO (1) | WO2018047792A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201812300A (zh) * | 2016-09-13 | 2018-04-01 | 日商富士麗比歐股份有限公司 | 心肌肌鈣蛋白之測定方法及測定試藥 |
CN113631924A (zh) * | 2019-05-24 | 2021-11-09 | 富士瑞必欧株式会社 | 甲状腺球蛋白的测定方法和测定试剂 |
CN117616277A (zh) | 2021-08-06 | 2024-02-27 | 株式会社先端生命科学研究所 | 甲状腺球蛋白的免疫检测及用于其的试剂盒 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000241429A (ja) | 1998-07-31 | 2000-09-08 | Mitsubishi Chemicals Corp | 生理活性成分の測定法 |
WO2014122973A1 (ja) | 2013-02-06 | 2014-08-14 | 富士レビオ株式会社 | 標的物質の測定方法 |
WO2016005328A2 (en) | 2014-07-07 | 2016-01-14 | AbbVie Deutschland GmbH & Co. KG | IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US820398A (en) | 1904-10-25 | 1906-05-15 | Samuel Cleland Davidson | Centrifugal fan or pump. |
US6100099A (en) | 1994-09-06 | 2000-08-08 | Abbott Laboratories | Test strip having a diagonal array of capture spots |
JPH08220099A (ja) | 1995-02-10 | 1996-08-30 | Morinaga Milk Ind Co Ltd | 物質の検出試薬及び慢性関節リウマチの検知法 |
WO2000007021A1 (fr) | 1998-07-31 | 2000-02-10 | Mitsubishi Chemical Corporation | Procede d'analyse d'un composant physiologiquement actif |
WO2005037209A2 (en) * | 2003-10-14 | 2005-04-28 | University Of South Florida | A method for the separation anti-amyloid beta antibody with amyloid beta peptide |
MXPA06004234A (es) * | 2003-10-15 | 2006-06-28 | Daiichi Pure Chemicals Co Ltd | Metodo de pretratamiento de la muestra y metodo de ensayo inmunologico utilizando el mismo. |
WO2005038457A1 (ja) | 2003-10-15 | 2005-04-28 | Daiichi Pure Chemicals Co., Ltd. | 多量体アディポネクチンの分別測定方法 |
EP1691198B1 (en) * | 2003-10-28 | 2010-10-20 | Advanced Life Science Institute, Inc. | Method of detecting hepatitis c virus |
US20070154976A1 (en) * | 2003-11-19 | 2007-07-05 | Daiichi Pure Chemicals Co., Ltd. | Method of determining substrate contained in hemoglobin-containing sample |
JP4197180B2 (ja) * | 2005-06-29 | 2008-12-17 | 株式会社シバヤギ | 検体中の内分泌物質測定方法 |
JP5420414B2 (ja) | 2006-10-06 | 2014-02-19 | シリゲン グループ リミテッド | 指向性バイオマーカシグナル増幅用の蛍光方法および材料 |
CN101017172A (zh) * | 2007-03-08 | 2007-08-15 | 湖南景达生物工程有限公司 | 一种测定丙型肝炎病毒总核心抗原的方法 |
US7807172B2 (en) * | 2007-06-13 | 2010-10-05 | University Of Washington | Methods and compositions for detecting thyroglobulin in a biological sample |
JP5759722B2 (ja) | 2007-08-28 | 2015-08-05 | アッヴィ バイオテクノロジー リミテッド | アダリムマブの結合蛋白質を含む組成物及び方法 |
US8475739B2 (en) | 2011-09-25 | 2013-07-02 | Theranos, Inc. | Systems and methods for fluid handling |
US10036745B2 (en) * | 2012-10-03 | 2018-07-31 | Gyros Patent Ab | Method and kit for analyte determination at acidic conditions |
CN102901812A (zh) * | 2012-11-13 | 2013-01-30 | 江阴泽成生物技术有限公司 | 一种人甲状腺球蛋白抗体(TGAb)的磁微粒化学发光免疫分析试剂盒及其检测方法 |
TW201812300A (zh) * | 2016-09-13 | 2018-04-01 | 日商富士麗比歐股份有限公司 | 心肌肌鈣蛋白之測定方法及測定試藥 |
-
2017
- 2017-09-05 EP EP21187667.7A patent/EP3929584A1/en active Pending
- 2017-09-05 EP EP17848732.8A patent/EP3511712B1/en active Active
- 2017-09-05 JP JP2018538407A patent/JP7007278B2/ja active Active
- 2017-09-05 WO PCT/JP2017/031869 patent/WO2018047792A1/ja unknown
- 2017-09-05 US US16/330,549 patent/US11768209B2/en active Active
- 2017-09-05 CN CN201780046303.9A patent/CN109477832A/zh active Pending
- 2017-09-05 CN CN202311191090.2A patent/CN117054645A/zh active Pending
- 2017-09-06 TW TW106130475A patent/TW201812298A/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000241429A (ja) | 1998-07-31 | 2000-09-08 | Mitsubishi Chemicals Corp | 生理活性成分の測定法 |
WO2014122973A1 (ja) | 2013-02-06 | 2014-08-14 | 富士レビオ株式会社 | 標的物質の測定方法 |
WO2016005328A2 (en) | 2014-07-07 | 2016-01-14 | AbbVie Deutschland GmbH & Co. KG | IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF |
Non-Patent Citations (1)
Title |
---|
西川光重ほか,サイログロブリン(Tg),日本臨床,2010年07月20日,68巻増刊号7,PP.295-298 |
Also Published As
Publication number | Publication date |
---|---|
WO2018047792A1 (ja) | 2018-03-15 |
CN109477832A (zh) | 2019-03-15 |
EP3511712B1 (en) | 2021-10-27 |
EP3511712A4 (en) | 2020-07-08 |
EP3929584A1 (en) | 2021-12-29 |
US20210215722A1 (en) | 2021-07-15 |
JPWO2018047792A1 (ja) | 2019-06-24 |
US11768209B2 (en) | 2023-09-26 |
TW201812298A (zh) | 2018-04-01 |
CN117054645A (zh) | 2023-11-14 |
EP3511712A1 (en) | 2019-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7060510B2 (ja) | 腫瘍マーカーの測定方法及び測定試薬 | |
JP6999561B2 (ja) | 心筋トロポニンの測定方法及び測定試薬 | |
JP7007278B2 (ja) | サイログロブリンの測定方法及び測定試薬 | |
JP2023017986A (ja) | 自己抗体の直接イムノアッセイ測定法 | |
JP7138627B2 (ja) | インスリンの測定方法及び測定試薬 | |
JP6399632B2 (ja) | 赤血球含有サンプル中の対象物を検出するためのイムノクロマトグラフィー用テストストリップ、および該テストストリップを使用するイムノクロマトグラフィー | |
CN115327121A (zh) | 凝血酶-抗凝血酶复合体的测定试剂及测定方法 | |
WO2020241443A1 (ja) | サイログロブリンの測定方法及び測定試薬 | |
WO2016098177A1 (ja) | 赤血球含有サンプル中の対象物を検出するためのイムノクロマトグラフィー用テストストリップ、および該テストストリップを使用するイムノクロマトグラフィー | |
WO2023013725A1 (ja) | サイログロブリンのイムノアッセイ及びそのためのキット | |
JP7157061B2 (ja) | ジカウイルスを検出する方法及びキット | |
WO2022154119A1 (ja) | 可溶性gpc3のイムノアッセイにおける可溶性gpc3含有検体の処理方法 | |
JP2024002311A (ja) | C-ペプチドの測定方法及びそのための試薬 | |
JP7055715B2 (ja) | ジカウイルス抗原および抗ジカウイルス抗体を検出するための方法およびキット | |
CN115280146A (zh) | 包含人iv型胶原7s结构域的片段的测定方法以及用于该测定方法的试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200813 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210302 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210426 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210701 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211222 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220106 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7007278 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |